Flinn Secures $20M to Enhance AI Automation for Medtech and Pharma Product Lifecycle Management
Flinn, based in Vienna, has raised $20 million in funding to develop AI tools for automating regulatory and quality processes in medtech and pharmaceuticals. The funding round was led by HV Capital, with backing from BHI - Bertelsmann Healthcare Investments and existing investors. The investment aims to expand Flinn’s platform across the entire product lifecycle and support international growth, particularly in the US market.
Theia Market Signal Identification - AI Assisted
Flinn has secured $20 million in funding to develop AI-powered software for automating regulatory and quality processes in medtech and pharmaceuticals. Led by HV Capital and supported by BHI - Bertelsmann Healthcare Investments, the funding will enable Flinn to extend its platform across the product lifecycle and enter the US market.
The company aims to improve operational efficiency and reduce compliance costs for manufacturers by automating workflows. Existing clients include Carl Zeiss and Philips. Flinn plans to enhance its infrastructure to cover earlier development stages and commercial processes, creating a unified compliance framework.
Comments